Editorial: Systemic Immune Dysregulation in Malignant Disease: Insights, Monitoring and Therapeutic Exploitation

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 20

PMID 37077834

Authors

Petros Christopoulos

Udo S Gaipl

Affiliations

Soon will be listed here.

References

Stepp W . High-Throughput NanoString Analysis of Oncogenic Human Papillomavirus and Tumor Microenvironment Transcription in Head and Neck Squamous Cell Carcinoma. Curr Protoc. 2021; 1(5):e146. PMC: 8204382. DOI: 10.1002/cpz1.146. View

Huang Z, Lin L, Liu Z, Hu C, Gu H, Wei R . m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma. Front Immunol. 2022; 12:765723. PMC: 8739240. DOI: 10.3389/fimmu.2021.765723. View

Christopoulos P, Schneider M, Bozorgmehr F, Kuon J, Engel-Riedel W, Kollmeier J . Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. Lung Cancer. 2018; 119:48-55. DOI: 10.1016/j.lungcan.2018.03.002. View

Poran A, Scherer J, Bushway M, Besada R, Balogh K, Wanamaker A . Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell Rep Med. 2020; 1(8):100141. PMC: 7691446. DOI: 10.1016/j.xcrm.2020.100141. View

Frey B, Ruckert M, Deloch L, Ruhle P, Derer A, Fietkau R . Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. Immunol Rev. 2017; 280(1):231-248. DOI: 10.1111/imr.12572. View

Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgauer M . Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2021; 71(2):251-265. PMC: 8783861. DOI: 10.1007/s00262-021-02981-w. View

Albakova Z, Mangasarova Y . The HSP Immune Network in Cancer. Front Immunol. 2021; 12:796493. PMC: 8669653. DOI: 10.3389/fimmu.2021.796493. View

Bazzi Z, Sneddon S, Zhang P, Tai I . Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. Front Immunol. 2023; 13:978862. PMC: 9945970. DOI: 10.3389/fimmu.2022.978862. View

Christopoulos P . Liquid biopsies come of age in lung cancer. Transl Lung Cancer Res. 2022; 11(5):706-710. PMC: 9186179. DOI: 10.21037/tlcr-22-268. View

10.

Elshiaty M, Schindler H, Christopoulos P . Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int J Mol Sci. 2021; 22(11). PMC: 8198225. DOI: 10.3390/ijms22115632. View

11.

Hao Z, Lin M, Du F, Xin Z, Wu D, Yu Q . Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer. Front Immunol. 2022; 12:754138. PMC: 8804248. DOI: 10.3389/fimmu.2021.754138. View

12.

Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgauer M . A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. Oncoimmunology. 2021; 10(1):1860586. PMC: 7808386. DOI: 10.1080/2162402X.2020.1860586. View

13.

Jiang A, Wu X, Wang D, Wang A, Dong K, Liu B . A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma. Front Immunol. 2022; 13:935595. PMC: 9355597. DOI: 10.3389/fimmu.2022.935595. View

14.

Christopoulos P, Fisch P . Acquired T-Cell Immunodeficiency in Thymoma Patients. Crit Rev Immunol. 2017; 36(4):315-327. DOI: 10.1615/CritRevImmunol.2017018916. View

15.

Yap T, Parkes E, Peng W, Moyers J, Curran M, Tawbi H . Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021; 11(6):1368-1397. PMC: 8178168. DOI: 10.1158/2159-8290.CD-20-1209. View

16.

Christopoulos P, Pfeifer D, Bartholome K, Follo M, Timmer J, Fisch P . Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011; 117(14):3836-46. DOI: 10.1182/blood-2010-07-299321. View

17.

Urban H, Steidl E, Hattingen E, Filipski K, Meissner M, Sebastian M . Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization. Front Immunol. 2022; 12:798811. PMC: 8761630. DOI: 10.3389/fimmu.2021.798811. View

18.

Schindler H, Lusky F, Daniello L, Elshiaty M, Gaissmaier L, Benesova K . Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors. Front Oncol. 2022; 12:1010660. PMC: 9662790. DOI: 10.3389/fonc.2022.1010660. View

19.

Meng L, Lu H, Li Y, Zhao J, He S, Wang Z . Human papillomavirus infection can alter the level of tumour stemness and T cell infiltration in patients with head and neck squamous cell carcinoma. Front Immunol. 2022; 13:1013542. PMC: 9676257. DOI: 10.3389/fimmu.2022.1013542. View

20.

Gaipl U, Multhoff G, Scheithauer H, Lauber K, Hehlgans S, Frey B . Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy. 2014; 6(5):597-610. DOI: 10.2217/imt.14.38. View